- Emgality has a list price of $575 a month, or $6,900 a year, matching the price set by the other two drugs in the class.
- Watch
ADVERTISEMENT
A new medication that's changing the way we treat a condition that affects 38 million Americans just got approved (LLY)
The FDA just approved a new preventative migraine medication made by drug giant Eli Lilly. The drug, Emgality, is the third in a competitive new class of medication going after the 38 million Americans who have migraines.
A human brain and its millions of small nerves
The FDA just approved a migraine treatment that's the first of a new class of medications.
The drug is called Emgality, and it's made by drug giant Eli Lilly. The drug has a list price of $575 a month, or $6,900 a year.
Until May, there weren't any drugs available today that were originally approved for alleviating migraines, though other treatments — including Botox and anti-seizure medications — have been used. Pain relievers can also help treat some of the symptoms of migraines.
ADVERTISEMENT
The drug — and its competitors — target CGRP, short for calcitonin gene-related peptide.
CGRP isn't exactly a new target. CGRP has been known to play a significant role in migraines since the 1980s and 1990s, though it's taken some time to develop the technology that can leverage it.
But in the past few months, the FDA has approved three preventative medications that act on the target.
Lilly's is the latest, and is a monthly injection. The company found in two phase 3 trials
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
ADVERTISEMENT